Navigation Links
Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model

Mymetics Also Announces Deal for Vaccine Delivery System

NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ -- Mymetics Corporation announced today that the Company's HIV vaccine elicited IgA mucosal antibodies in a non-human primate model. Mucosal IgA antibodies are considered a possible first line of defense against infection by HIV. The data were presented by Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer in an oral presentation, "Without Mucosal Adjuvant, Virosomes-gp41 Peptides from the MPR can Elicit Protective Mucosal IgA in Vaccinated Macaques," at the Keystone Symposium, HIV Vaccines: From Basic Research to Clinical Trials. The meeting is being supported by the Bill & Melinda Gates Foundation.

"The results are a striking example of the progress we have seen in applying our vaccine based on the gp41, a well-conserved HIV surface membrane protein," commented Dr. Fleury. "Previously, our team was the first to be able to synthesize a trimeric, soluble and stable formulation of gp41 that could be used in a vaccine. Now, by showing that we can elicit IgA mucosal antibodies in vaginal and rectal tissues, we have taken a major step in being able to prepare materials for a submission to begin studies in human patients. We expect that this submission could take place as early as the third quarter of 2008."

Mymetics also announced that it has signed an exclusive license with Pevion Biotech for the use of Virosomes(R) in the production of its HIV vaccine. Virosomes are a market-approved carrier system for the delivery of pharmaceutically or immunologically active substances, allowing the correct spatial presentation of peptides and proteins and facilitating delivery of Mymetics' HIV vaccine without the use of an adjuvant. Additional details were not disclosed.

Christian Rochet, Mymetics' President and Chief Executive Officer, stated, "We believe that our exclusive agreemen t with Pevion provides a competitive advantage by allowing us to avoid using an adjuvant for our HIV vaccine. We view this as a strategic advantage since it is our belief that adjuvants have not sufficiently advanced to enter clinical testing for HIV vaccines."

Mymetics Vaccine Program Background

Worldwide, over 85% of HIV infections are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen or secretions. According to a recent report from the International AIDS Vaccine Initiative, "Since an effective preventive AIDS vaccine will primarily have to protect an individual from sexual transmission of HIV, researchers think it will probably be important for a vaccine candidate to induce strong mucosal immune responses." Mymetics-affiliated researchers have been able to engineer gp41-derived antigens (proteins and peptides) capable of eliciting antibodies, particularly IgA antibodies, with strong potential for preventing in vitro virus translocation across the mucosal barrier and/or to inhibit cell infection, thus preventing HIV-1 infection.

    Mymetics has combined three important concepts in its vaccine design:

    1- Induction of mucosal and blood antibodies to allow protection in

       different anatomical compartments and block the early event of HIV

       translocation at the genito-reproductive and intestine tracts and

       subsequent infection of target cells underlying the mucosal tissues,

       thereby preventing HIV entry and spreading in the body.

    2- Focusing the immune response against conserved regions on gp41 that may

       induce protective antibodies against a broad range of HIV clades.

       Mymetics is developing vaccines that contain antigens expressing

       limited immunodominant regions, while immunodistractive regions have

       been removed or altered without affecting the immunogenicity of the


    3- Minimal mimicry.  Underlying its vaccine program is Mymetics' key

       discovery of a fundamental though subtle three-dimensional mimicry

       between the viral envelope glycoprotein gp41 and the IL-2 cytokine

       (Interleukin-2) of the infected host.  Mymetics strongly believes that

       it is crucial to prevent the potential induction of cross-reactivity

       toward self-proteins, such as IL-2, post-vaccination in order to

       prevent potential long term autoimmune negative side-effects.

    About Mymetics

Mymetics was founded in 1990 near Lyon, France and was registered as a US (Delaware) public company in 2000. Since August 2003, its operations and research programs have been managed out of Switzerland (Nyon, near Geneva).

Mymetics Common shares trade on NASDAQ's OTC:PK under the symbol MYMX. For more information, please visit the Company's website at

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions.

The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the adminis tration of such laws. See Mymetics' Form 10-K for the fiscal years ended December 31, 2005 and December 31, 2006 for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

CONTACT: Ernest Luebke, CFO, Mymetics Corp., +41-22-363-1310,

Web site:

Ticker Symbol: (NASDAQ-NMS:MYMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
6. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
10. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
Post Your Comments:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):